OncoMatch/Clinical Trials/NCT07117890
Sunvozertinib Treatment in Untreated Advanced NSCLC With EGFR Uncommon Mutations
Is NCT07117890 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including sunvozertinib 300mg and sunvozertinib 200mg for non small cell lung cancer.
Treatment: sunvozertinib 300mg · sunvozertinib 200mg — This study is a single arm study to access the anti-tumor efficacy and safety of sunvozertinib in untreated advanced NSCLC patients with EGFR uncommon mutations.
Check if I qualifyExtracted eligibility criteria
Cancer type
Small Cell Lung Cancer
Biomarker criteria
Required: EGFR uncommon mutation (excluding 19del, L858R, T790M, Ex 20ins)
documented EGFR uncommon mutations from a local laoratory. at least one EGFR uncommon mutation (excluding EGFR 19del/l858r/T790m/Ex 20ins ) or compund mutations with EGFR uncommon mutations.
Prior therapy
Cannot have received: systemic anti-tumor therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify